Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.

View Full Paper
Ask AI
Bookmark
Share

Authors

FCFrancesco CorradoNBNayda BidikianMTMichael Timonian

Discussion

Loading...

Member takes

Overview

Analysis reveals higher T cell activation and differentiation in high-risk smoldering myeloma patients, suggesting better responses to CAR-T and bAbs.

Key Points

  • Patients with high-risk smoldering myeloma exhibited enhanced immune responses to CAR-T cell therapies.
  • At Day 28, these patients had higher frequencies of activated T cells and greater stemness expression.
  • Single-cell RNA and T cell receptor sequencing assessed immune profiles from peripheral blood and bone marrow samples.
  • Results imply that strong pre-treatment immune capacity may enhance therapeutic responses in these patients.

Cite This Study

Corrado et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dca6https://doi.org/10.1182/blood-2025-921
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Functional fitness of CAR-T cells in the bone marrow following anti-BCMA durcabtagene autoleucel (PHE885) therapy correlate with prolonged PFS in RRMM2025
  2. 2The dynamic landscape of immune environment for MM patients receiving T cell redirectiing therapies2025
  3. 3Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy2025
  4. 4CAR-T cells manufactured after multiple myeloma triplet or quadruplet induction therapy have reduced functionality and an altered composition2025
  5. 5Real-world comparison of CAR T-cell therapy versus bispecific antibodies in relapsed or refractory multiple myeloma2025 · 1 citations